Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimeC phase 2 trial in mild to moderate Alzheimer's disease
MOH_2023-07-18_012826Phase 2Recruiting
- Sponsor
- NeuroSense Therapeutics
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing PrimeC + standard treatment with Placebo + standard treatment (2 arms). Primary endpoints: Safety and tolerability and Efficacy. Started Sep 2023; status: recruiting.
02
Drugs
PrimeC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2023-07-18_012826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-18_012826.